X4 Pharmaceuticals (NASDAQ:XFOR) Given New $4.00 Price Target at Stifel Nicolaus

X4 Pharmaceuticals (NASDAQ:XFOR) had its price target reduced by Stifel Nicolaus from $5.00 to $4.00 in a research report sent to investors on Thursday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

X4 Pharmaceuticals Price Performance

Shares of X4 Pharmaceuticals stock opened at $0.40 on Thursday. The firm has a market cap of $68.82 million, a PE ratio of -4.48 and a beta of 0.39. X4 Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $1.60. The company has a quick ratio of 6.04, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The company’s fifty day simple moving average is $0.58 and its two-hundred day simple moving average is $0.74.

Insiders Place Their Bets

In related news, COO Mary Dibiase sold 67,695 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. The trade was a 13.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam S. Mostafa sold 230,645 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The disclosure for this sale can be found here. Insiders have sold a total of 580,800 shares of company stock valued at $321,447 in the last quarter. Insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP purchased a new position in X4 Pharmaceuticals in the third quarter worth about $340,000. K2 Principal Fund L.P. purchased a new position in X4 Pharmaceuticals in the second quarter worth about $284,000. AQR Capital Management LLC raised its holdings in X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after buying an additional 388,115 shares during the last quarter. State Street Corp raised its holdings in X4 Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares during the last quarter. Finally, Barclays PLC raised its holdings in X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock worth $185,000 after buying an additional 183,861 shares during the last quarter. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.